---
schema_version: "secwatch.filing_event.v1"
accession: "0001013762-23-002000"
form_type: "8-K"
ticker: "LGVN"
cik: "0001721484"
company_name: "Longeveron Inc."
filed_at: "2023-10-05T23:59:59+00:00"
generated_at: "2026-06-10T04:04:28.651952+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Longeveron announces positive Phase 2a top-line results for Lomecel-B in mild Alzheimer's disease

## Summary
- Primary safety endpoint met; one SAE per Lomecel-B group, none on placebo, DSMB no issues.
- Secondary endpoint CADS showed statistical improvement for 25M single dose (p=0.091) and pooled groups (p=0.099) vs placebo at week 39.
- Lomecel-B low-dose (25M x1) significantly slowed left hippocampal volume loss (p=0.015) vs placebo.
- Pooled Lomecel-B groups showed significant improvement in ADCS-ADL (p=0.047) at week 39.
- Webcast and conference call held Oct 5, 2023 at 8:00 AM ET to discuss results.

## SEC filing metadata
- accession: 0001013762-23-002000
- form_type: 8-K
- ticker: LGVN
- cik: 0001721484
- company_name: Longeveron Inc.
- filed_at: 2023-10-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1721484/000101376223002000/0001013762-23-002000-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1721484/000101376223002000/ea186354-8k_longeveron.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001013762-23-002000
- JSON: https://secwatch.observer/filing/0001013762-23-002000.json
- Plain text: https://secwatch.observer/filing/0001013762-23-002000.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.